HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

483.155

-13.603-2.74%

Number of Gainers:7

Number of Losers:23

Number of Flat:3

PE:- -

High:496.758

Open:496.758

Low:480.328

Close:496.758

Volume:115.32M

Turnover:2.61B

Market Cap:306.93B

Float Cap:273.30B

Loading ...

Hong Kong Stocks Fall as Oil Extends Rally; Venus Medtech Gains

MT Newswires Live

Anglikang's In-Licensing Deal Collapses: Core Business Pressures Compound Innovation Pipeline Uncertainty

MEDCAPTAIN's Hong Kong IPO: A Medical Device Empire Built on Acquisitions Faces Multiple Headwinds

Apichope's gout drug AR882 meets primary endpoint in Phase III trial with projected peak sales of 1.95 billion yuan in Greater China

Nicox Says China Regulator Accepts NCX 470 NDA for Review

TYK Medicines-B (02410): Short-Term Volatility Masks Long-Term Strength, Insider Buying and Solid Fundamentals Open Up an Attractive Entry Point

Ocumension's NDA For Ocular Treatment Approved in China

MT Newswires Live

HK Stock Market Update | Innovative Drug Stocks Face Continued Pullback Amid Shifting Overseas Rate Expectations and Post-2026 Negotiation Uncertainty

Hong Kong Stock Market Flash | TYK Medicines-B Surges Over 9% as Chairman's Share Buyback Reinforces Confidence and Novel EGFR-TKI Gains Landmark Approval

HK Business Breakthrough Drives Nearly 5% Intraday Rally for CARSGEN-B

Regulatory Intervention Halts Trading of Eye-Care Drug Developer Following Suspected IPO Irregularities

Venus Medtech Plans 500 Million Yuan Share, Convertible Bond Subscription

MT Newswires Live

Ocumension Therapeutics Says NMPA Accepts NDA for OT-301 (NCX 470, Bimatoprost Grenod)

OCUMENSION-B (01477) NDA for OT-301 Accepted by Chinese Drug Regulator

Ocumension Says China NMPA Accepts OT-301 Glaucoma Drug Application

Ocumension Therapeutics - Nmpa Accepts Nda for Ot-301 (Ncx 470, Bimatoprost Grenod) in China

THOMSON REUTERS

HBM Holdings FY26 H1 Profit Falls 11.16% to US$ 64.85 Million; Revenue Rises 20.9% to US$ 122.49 Million

Venus Medtech Hangzhou - to Issue 184.5 Mln Shares and Hk$379.7 Mln Convertible Bonds

THOMSON REUTERS

Venus Medtech Hangzhou - Subscription Price Per Share is Hk$1.078

THOMSON REUTERS

Venus MedTech Agrees Private Placement of 184,536,703 Shares at HKD 1.08 Each

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/BK1574/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":483.15506,"timestamp":1789114133774,"preClose":496.75812,"halted":0,"volume":115323363,"delay":0,"changeRate":-0.027384,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-13.603058,"latestTime":"09-11 16:00:00","open":496.75812,"high":496.75812,"low":480.32812,"amount":2611810568,"amplitude":0.033074,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"pbRate":3.606253,"peRate":160.422718,"turnoverRate":0.004215,"increases":6,"decrements":25,"flats":1,"marketCap":306930068880,"floatMarketCap":273297591592},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":496.75812,"amplitude":0.033074,"preClose":496.75812,"low":480.32812,"pbRate":"3.606253","latestPrice":483.15506,"volume":115323363,"delay":0,"open":496.75812,"prevYearClose":556.26263,"prevWeekClose":483.155,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":532.025,"twentyDayClose":518.327,"sixtyDayClose":434.471,"secType":"PLATE","market":"HK","turnoverRate":0.004215,"peRate":160.422718,"marketCap":306930068880,"floatMarketCap":273297591592,"timestamp":1789114133774,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":7,"down":23,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666473665","title":"Hong Kong Stocks Fall as Oil Extends Rally; Venus Medtech Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2666473665","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666473665?lang=en_us&edition=fundamental","pubTime":"2026-09-11 16:36","pubTimestamp":1789115807,"startTime":"0","endTime":"0","summary":"Hong Kong stocks closed lower Friday as surging oil prices stoked inflation concerns.The Hang Seng Index fell 148.84 points, or 0.6%, to close at 24,805.63, while the Hang Seng China Enterprises Index lost 28.45 points, or 0.3%, to finish at 8,246.33.Brent crude rose as much as 6% to $109.97 a barrel, its highest in four months, and was on track for an 11% weekly gain as fighting between the U.S. and Iran disrupted oil flows through the Strait of Hormuz.Investors awaited U.S. August inflation data for further clues on the Fed's policy path, with core CPI forecast to rise 0.2% month-over-month.Higher oil prices and sticky inflation have also prompted JPMorgan to expect eight of nine developed-market central banks to raise rates by year-end.In corporate news, Venus Medtech  closed 5% higher after agreeing to subscribe for 500 million yuan of shares and convertible bonds.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["83115","02833","02500","HHImain","07200","07300","03037","BK1100","BK1583","03115","MHImain","09115","03419","BK1574","MCHmain","02800","513600","HSI","82800","HSTECH","07500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143437713","title":"Anglikang's In-Licensing Deal Collapses: Core Business Pressures Compound Innovation Pipeline Uncertainty","url":"https://stock-news.laohu8.com/highlight/detail?id=1143437713","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143437713?lang=en_us&edition=fundamental","pubTime":"2026-09-11 15:41","pubTimestamp":1789112501,"startTime":"0","endTime":"0","summary":"Zhejiang Anglikang Pharmaceutical Co.,Ltd. announced on September 6 that it has terminated its licensing agreement with Yafei Bio and Qinheli for the IMD-1005 (ALKN002) tumor-targeting antibody...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNGR","BK1574","159992","BK1161","06978","IBBQ","MEDX","002940","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188732548","title":"MEDCAPTAIN's Hong Kong IPO: A Medical Device Empire Built on Acquisitions Faces Multiple Headwinds","url":"https://stock-news.laohu8.com/highlight/detail?id=1188732548","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188732548?lang=en_us&edition=fundamental","pubTime":"2026-09-11 15:40","pubTimestamp":1789112453,"startTime":"0","endTime":"0","summary":"MEDCAPTAIN has officially launched its global offering on the Hong Kong stock exchange. Originating from a small infusion equipment manufacturer, the company has leveraged capital support and...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGHT","PTH","RSPH","BK1583","BK4585","GDOC","XMMO","HART","MEDX","MDEV","IEIH","KCE","MYLD","BK1100","159883","09996","LNGR","BK1574","BK4588","CALF","AGNG","02041"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130333927","title":"Apichope's gout drug AR882 meets primary endpoint in Phase III trial with projected peak sales of 1.95 billion yuan in Greater China","url":"https://stock-news.laohu8.com/highlight/detail?id=1130333927","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130333927?lang=en_us&edition=fundamental","pubTime":"2026-09-11 15:40","pubTimestamp":1789112442,"startTime":"0","endTime":"0","summary":"Apichope Pharmaceutical Group Co.,Ltd. has voluntarily disclosed that its gout innovation drug AR882 has achieved the primary endpoint in a Phase III clinical study for treating gout patients with...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","IBBQ","MEDX","BK1574","300723","LNGR","159992","BK0239","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666545670","title":"Nicox Says China Regulator Accepts NCX 470 NDA for Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2666545670","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666545670?lang=en_us&edition=fundamental","pubTime":"2026-09-11 13:30","pubTimestamp":1789104621,"startTime":"0","endTime":"0","summary":"Nicox says China regulator accepts NCX 470 NDA for reviewChina’s NMPA accepted for review the New Drug Application for Nicox’s NCX 470 glaucoma treatment, filed by licensee Ocumension Therapeutics.Reg","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDLbX7Rg0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BCDF","LU0314104364.USD","LU2210149790.SGD","01477","SG9999014021.USD","SG9999014005.SGD","BK4112","IE00BQXX3D17.EUR","IE00BN0W2W23.USD","SG9999014013.SGD","LU2095319765.USD","NDAQ","BK1191","LU2210150020.SGD","IE00BQXX3C00.GBP","IE00B64PRP62.GBP","BK4588","IE00BQXX3F31.USD","IE00BGHQF748.EUR","BK4585","BK1574","SG9999014039.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173137297","title":"TYK Medicines-B (02410): Short-Term Volatility Masks Long-Term Strength, Insider Buying and Solid Fundamentals Open Up an Attractive Entry Point","url":"https://stock-news.laohu8.com/highlight/detail?id=1173137297","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173137297?lang=en_us&edition=fundamental","pubTime":"2026-09-11 13:20","pubTimestamp":1789104027,"startTime":"0","endTime":"0","summary":"Recent turbulence in the Hong Kong-listed pharmaceutical sector, driven by interim earnings season, Hang Seng Connect eligibility adjustments, capital rotation, and shifting Fed rate hike...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","BK1515","02410","BK1574","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666254535","title":"Ocumension's NDA For Ocular Treatment Approved in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2666254535","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666254535?lang=en_us&edition=fundamental","pubTime":"2026-09-11 13:16","pubTimestamp":1789103801,"startTime":"0","endTime":"0","summary":"Ocumension Therapeutics  said Friday that the Chinese healthcare regulator approved its new drug application for OT-301, its proposed treatment for glaucoma or ocular hypertension-related complications, according to a same-day bourse filing.The pharmaceutical company said the approval follows the completion of the Mont Blanc and Denali trials of OT-301, in which the treatment achieved key study goals.The company's shares are down 2.8% in afternoon trading on the HKEX.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01477","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115866351","title":"HK Stock Market Update | Innovative Drug Stocks Face Continued Pullback Amid Shifting Overseas Rate Expectations and Post-2026 Negotiation Uncertainty","url":"https://stock-news.laohu8.com/highlight/detail?id=1115866351","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115866351?lang=en_us&edition=fundamental","pubTime":"2026-09-11 11:13","pubTimestamp":1789096425,"startTime":"0","endTime":"0","summary":"Innovative drug concept stocks are experiencing sustained downward pressure in Hong Kong trading. As of the latest update, LEPU BIO (02157) has declined 3.91% to HK$38.05, while REMEGEN (09995) fell...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK4588","LU1226288253.USD","01801","LU0502904849.HKD","LU1993786604.SGD","LU1152091754.HKD","LU0140636845.USD","LU2097828557.USD","LU1152091168.USD","LU2097828805.USD","LU1951186391.HKD","02157","IE00B543WZ88.USD","LU0244354667.USD","LU1226287792.SGD","WRTH","BK1515","IE00BZ08YR35.GBP","IBBQ","LU1226288170.HKD","LU2097828631.EUR","LU2328871848.SGD","BK4585","LU0880133367.SGD","LU1188198961.HKD","LU2097828474.EUR","LU1807302812.USD","LU1969619763.USD","LU2242644610.SGD","LU0067412154.USD","BK1191","LU0463099449.HKD","06978","IE00B5MMRT66.SGD","LU0314109678.HKD","159992","LU2488822045.USD","BK1161","LU1328277881.USD","LU1960683339.HKD","LU0149534421.HKD","09995","LU0607220059.USD","IE0008368742.USD","LU1226287875.USD","PEVC","LU0501845795.SGD","01093","IE00B031HY20.USD","BK1583","LU0455707207.USD","MEDX","LU2039709279.SGD","SG9999004220.SGD","BK1521","LU0315179316.USD","KCAI","BK1589","MCRO","HK0000165453.HKD","KURE","LU1008478684.HKD","LU2097828714.EUR","LU1226287529.USD","LU0326950275.SGD","LU1813983027.USD","LNGR","VXUS","IE00BZ08YT58.USD","LU0072913022.USD","IE00BZ08YS42.EUR","IE0008369823.USD","LU1831875114.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138018938","title":"Hong Kong Stock Market Flash | TYK Medicines-B Surges Over 9% as Chairman's Share Buyback Reinforces Confidence and Novel EGFR-TKI Gains Landmark Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1138018938","media":"Stock News","labels":["shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138018938?lang=en_us&edition=fundamental","pubTime":"2026-09-11 11:08","pubTimestamp":1789096097,"startTime":"0","endTime":"0","summary":"TYK Medicines-B (02410) saw its shares climb sharply this morning, jumping more than 9% in early trading. As of the latest update, the stock was up 9.7% at HK$2.94, with trading turnover reaching...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410","BK1515","159938","KCAI","BK1161","BK1574","VXUS","BK4588","BK4585","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195415295","title":"HK Business Breakthrough Drives Nearly 5% Intraday Rally for CARSGEN-B","url":"https://stock-news.laohu8.com/highlight/detail?id=1195415295","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195415295?lang=en_us&edition=fundamental","pubTime":"2026-09-11 10:50","pubTimestamp":1789095018,"startTime":"0","endTime":"0","summary":"CARSGEN-B (02171) saw its share price climb nearly 5% during intraday trading, building on optimistic market sentiment. As of the latest update, shares were up 1.84%, trading at HKD 12.70 with a...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1587","BK1161","02171","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140079980","title":"Regulatory Intervention Halts Trading of Eye-Care Drug Developer Following Suspected IPO Irregularities","url":"https://stock-news.laohu8.com/highlight/detail?id=1140079980","media":"Deep News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140079980?lang=en_us&edition=fundamental","pubTime":"2026-09-11 10:00","pubTimestamp":1789092059,"startTime":"0","endTime":"0","summary":"Hong Kong's securities regulator has ordered the suspension of trading in shares of Cloudbreak Pharma (02592.HK), citing serious concerns that the company's initial public offering may have been...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","MEDX","LNGR","BK4127","06978","BK1574","KCE","159992","FRHC","REDS","IBBQ","02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666517821","title":"Venus Medtech Plans 500 Million Yuan Share, Convertible Bond Subscription","url":"https://stock-news.laohu8.com/highlight/detail?id=2666517821","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666517821?lang=en_us&edition=fundamental","pubTime":"2026-09-11 09:43","pubTimestamp":1789091017,"startTime":"0","endTime":"0","summary":"Venus Medtech  entered into a subscription agreement with Hangzhou Yingzhiqin No. 3 Equity Investment Partnership for up to 500 million yuan of new shares and convertible bonds, according to a Thursday Hong Kong bourse filing.The deal comprises 184.5 million new shares for about 171.9 million yuan and convertible bonds of up to HK$379.7 million.The subscription price is HK$1.078 per share, while the initial conversion price is HK$1.1858.The company said the fundraising will help address liquidity needs, meet near-term financial obligations, and support operations and product development.The subscription remains subject to shareholder and other regulatory approvals.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","US12M.BOND","02500","US5Y.BOND","TLTW","US6M.BOND","US7Y.BOND","TMF","US2Y.BOND","US10Y.BOND","BK1100","US30Y.BOND","BK1574","TLT","US3Y.BOND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666451972","title":"Ocumension Therapeutics Says NMPA Accepts NDA for OT-301 (NCX 470, Bimatoprost Grenod)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666451972","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666451972?lang=en_us&edition=fundamental","pubTime":"2026-09-11 07:11","pubTimestamp":1789081906,"startTime":"0","endTime":"0","summary":"Sept 11 (Reuters) - Ocumension Therapeutics <1477.HK>::*NMPA ACCEPTS NDA FOR OT-301 (NCX 470, BIMATOPROST GRENOD) IN CHINA*Further company coverage: 1477.HK* ((Reuters.Briefs@thomsonreuters.com;))((Re","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nRSD431L9q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147207766","title":"OCUMENSION-B (01477) NDA for OT-301 Accepted by Chinese Drug Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=1147207766","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147207766?lang=en_us&edition=fundamental","pubTime":"2026-09-11 07:10","pubTimestamp":1789081826,"startTime":"0","endTime":"0","summary":"OCUMENSION-B (01477) has announced that its New Drug Application (NDA) for OT-301 (NCX 470, Gebe前列素) has been accepted by the Center for Drug Evaluation of China's National Medical Products...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1191","01477","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666478519","title":"Ocumension Says China NMPA Accepts OT-301 Glaucoma Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2666478519","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666478519?lang=en_us&edition=fundamental","pubTime":"2026-09-11 07:00","pubTimestamp":1789081240,"startTime":"0","endTime":"0","summary":"Ocumension says China NMPA accepts OT-301 glaucoma drug applicationOcumension Therapeutics’ China regulator accepted an NDA for OT-301 to lower intraocular pressure in open-angle glaucoma or ocular hy","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDL12b5tR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666551942","title":"Ocumension Therapeutics - Nmpa Accepts Nda for Ot-301 (Ncx 470, Bimatoprost Grenod) in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2666551942","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666551942?lang=en_us&edition=fundamental","pubTime":"2026-09-11 07:00","pubTimestamp":1789081227,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nFWN4520Z5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666599377","title":"HBM Holdings FY26 H1 Profit Falls 11.16% to US$ 64.85 Million; Revenue Rises 20.9% to US$ 122.49 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2666599377","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666599377?lang=en_us&edition=fundamental","pubTime":"2026-09-10 21:38","pubTimestamp":1789047495,"startTime":"0","endTime":"0","summary":"HBM Holdings FY26 H1 profit falls 11.16% to US$ 64.85 million; revenue rises 20.9% to US$ 122.49 millionHBM Holdings reported 2026 first-half revenue up 20.9% to US$122.49 million, while profit fell 1","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDL9BfBQl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","02142","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666969115","title":"Venus Medtech Hangzhou - to Issue 184.5 Mln Shares and Hk$379.7 Mln Convertible Bonds","url":"https://stock-news.laohu8.com/highlight/detail?id=2666969115","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666969115?lang=en_us&edition=fundamental","pubTime":"2026-09-10 21:12","pubTimestamp":1789045939,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nFWN4520CM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1100","02500","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666596916","title":"Venus Medtech Hangzhou - Subscription Price Per Share is Hk$1.078","url":"https://stock-news.laohu8.com/highlight/detail?id=2666596916","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666596916?lang=en_us&edition=fundamental","pubTime":"2026-09-10 21:12","pubTimestamp":1789045939,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nFWN4520CM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","02500","BK1583","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666596961","title":"Venus MedTech Agrees Private Placement of 184,536,703 Shares at HKD 1.08 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2666596961","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666596961?lang=en_us&edition=fundamental","pubTime":"2026-09-10 21:11","pubTimestamp":1789045904,"startTime":"0","endTime":"0","summary":"Venus MedTech agrees private placement of 184,536,703 shares at HKD 1.08 eachVenus Medtech signed a subscription agreement on Sept. 10, 2026 for 184,536,703 new shares at HKD 1.08.Share sale size: HKD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDL1grvnL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02500","BK1583","BK1574","BK1100"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":2,"totalSize":252,"code":"91000000","status":"200"}]}}